Wide Ranks

CRBU

Caribou Biosciences, Inc.

2.20

Top Statistics
Market Cap 199 M Forward PE -1.06 Revenue Growth -91.40 %
Current Ratio 7.38 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.0150 Enterprise / Revenue -0.2020 Price To Sales Trailing12 Months 17.36
Profitability
Profit Margins 0.00 % Operating Margins -1666.90 %
Balance Sheet
Total Cash 228 M Total Cash Per Share 2.52 Total Debt 26 M
Total Debt To Equity 9.47 Current Ratio 7.38 Book Value Per Share 3.10
All Measures
Short Ratio 478.00 % Message Board Id finmb_272189231 Shares Short Prior Month 11 M
Return On Equity -0.4360 City Berkeley Uuid f11f6be1-a9a3-3c9c-bdb1-a1f42c197bdb
Previous Close 2.02 First Trade Date Epoch Utc 1 B Book Value 3.10
Beta 2.26 Total Debt 26 M Volume 2 M
Price To Book 0.7085 Fifty Two Week Low 1.50 Total Cash Per Share 2.52
Total Revenue 11 M Shares Short Previous Month Date 1 B Target Median Price 11.50
Max Age 86400 Recommendation Mean 1.67 Sand P52 Week Change 0.3133
Operating Margins -1666.90 % Target Mean Price 12.50 Net Income To Common -148120000
Short Percent Of Float 0.0858 Implied Shares Outstanding 90 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M Average Volume10days 1 M
Total Cash 228 M Next Fiscal Year End 1 B Revenue Per Share 0.1280
Held Percent Insiders 0.1004 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 2.02 Target Low Price 3.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.04 Open 2.02
Free Cashflow -78726872 State CA Dividend Yield 0.00 %
Return On Assets -0.2514 Time Zone Short Name EST Trailing Eps -1.66
Day Low 2.00 Address1 2929 7th Street Shares Outstanding 90 M
Price Hint 4 Target High Price 26.00 Website https://cariboubio.com
52 Week Change -0.6252 Average Volume 1 M Forward Eps -1.99
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 717.80 %
Is_sp_500 False Regular Market Day High 2.20 Profit Margins 0.00 %
Debt To Equity 9.47 Fifty Two Week High 8.33 Day High 2.20
Shares Short 7 M Regular Market Open 2.02 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue -0.2020 Revenue Growth -91.40 %
Shares Percent Shares Out 0.0819 Operating Cashflow -124109000 Currency USD
Time Zone Full Name America/New_York Market Cap 199 M Is_nasdaq_100 False
Zip 94710 Quote Type EQUITY Industry Biotechnology
Long Name Caribou Biosciences, Inc. Regular Market Day Low 2.00 Held Percent Institutions 0.6257
Current Price 2.20 Address2 Suite 105 Enterprise To Ebitda 0.0150
Financial Currency USD Current Ratio 7.38 Industry Disp Biotechnology
Number Of Analyst Opinions 8 Country United States Float Shares 81 M
Two Hundred Day Average 3.10 Enterprise Value -2321088 Price To Sales Trailing12 Months 17.36
Forward PE -1.06 Regular Market Volume 2 M Ebitda -157800000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally.

Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.

The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia.

Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.